31 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
23777782	107	Orally available and efficaciousa4ß1/a4ß7 integrin inhibitors.	Elan Pharmaceuticals
23562062	4	Arylsulfonamide pyrimidines as VLA-4 antagonists.	Elan Pharmaceuticals
23312474	36	Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4-beta1 and alpha4-beta7 receptor antagonists.	Hoffmann-La Roche
23312471	31	Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual actinga4ß1 anda4ß7 receptor antagonists.	Hoffmann-La Roche
18331794	20	Selective cell adhesion inhibitors: Barbituric acid based alpha4beta7--MAdCAM inhibitors.	Millennium Pharmaceuticals
18226905	60	Synthesis and SAR of pyridazinone-substituted phenylalanine amide alpha4 integrin antagonists.	Johnson & Johnson Pharmaceutical Research & Development
12139455	78	Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.	Genentech
17118652	15	Highly constrained bicyclic VLA-4 antagonists.	Merck Research Laboratories
15081035	24	Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.	Merck Research Laboratories
15081033	21	Amidines as amide bond replacements in VLA-4 antagonists.	Merck Research Laboratories
12617914	116	N-(3-phenylsulfonyl-3-piperidinoyl)-phenylalanine derivatives as potent, selective VLA-4 antagonists.	Merck Research Laboratories
12270174	34	Solid-phase synthesis of dual alpha4beta1/alpha4beta7 integrin antagonists: two scaffolds with overlapping pharmacophores.	Genentech
12127538	26	N-aryl-prolyl-dipeptides as potent antagonists of VLA-4.	Merck Research Laboratories
12127523	22	N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists.	Merck Research Laboratories
12031329	110	Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.	Merck Research Laboratories
11844689	51	Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.	Merck Research Laboratories
11755344	47	The discovery of small molecule carbamates as potent dual alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.	Merck Research Laboratories
11755338	24	Specific and dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) integrins.	Merck Research Laboratories
11677134	42	Design and synthesis of potent and selective inhibitors of integrin VLA-4.	Novartis Institute For Biomedical Research
11591507	79	The discovery of sulfonylated dipeptides as potent VLA-4 antagonists.	Merck Research Laboratories
11472212	6	Design and synthesis of potent and selective alpha(4)beta(7) integrin antagonists.	Technische UniversitäT MüNchen
31266686	7	Small-molecule agents for the treatment of inflammatory bowel disease.	Gilead Sciences
10915035	16	Cell adhesion antagonists: synthesis and evaluation of a novel series of phenylalanine based inhibitors.	Millennium Pharmaceutical
10853677	34	Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.	Celltech Chiroscience
10072689	39	Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.	Biogen
26101577	15	Dehydro-?-proline Containing ?4?1 Integrin Antagonists: Stereochemical Recognition in Ligand-Receptor Interplay.	University of Bologna
24568695	76	Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.	University of Bradford
16495061	8	Selection of a 2-azabicyclo[2.2.2]octane-based alpha4beta1 integrin antagonist as an inhaled anti-asthmatic agent.	Johnson & Johnson Pharmaceutical
16112583	74	Aza-bicyclic amino acid carboxamides as alpha4beta1/alpha4beta7 integrin receptor antagonists.	Johnson & Johnson Pharmaceutical
16722660	60	Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.	Johnson & Johnson Pharmaceutical